GDF-11 Activators
The chemical class of GDF-11 activators encompasses a diverse array of compounds that modulate the activity of Growth Differentiation Factor 11 (GDF-11), a member of the TGF-β superfamily known for its regulatory roles in various biological processes. These activators can be broadly classified into direct and indirect activators, each influencing GDF-11 activity through distinct mechanisms. Direct activators, including LDN-212854, DMH1, and Noggin, interact directly with GDF-11 or its associated receptors, modulating its signaling cascade. LDN-212854 and DMH1 selectively inhibit BMP receptors, indirectly leading to increased GDF-11 levels by relieving repression on its expression. Noggin, a BMP antagonist, blocks BMP signaling, allowing for enhanced GDF-11 expression. These direct activators exemplify the potential of targeted interventions to modulate GDF-11 levels through direct interactions with its signaling components.
Indirect activators, such as Dorsomorphin, SB431542, and Galunisertib, influence GDF-11 levels by targeting key signaling pathways. Dorsomorphin, an AMPK inhibitor, indirectly activates GDF-11 by suppressing AMPK activity. SB431542 and Galunisertib, selective inhibitors of TGF-β type I receptors, indirectly activate GDF-11 by blocking TGF-β signaling. These indirect activators highlight the intricate crosstalk between GDF-11 and various signaling pathways, offering potential avenues for modulating GDF-11 levels in diverse cellular contexts. Valproic Acid and DAPT, which modulate histone acetylation and Notch signaling, respectively, represent additional indirect activators influencing GDF-11 levels. These compounds showcase the diverse regulatory mechanisms that can be targeted to modulate GDF-11 expression and function. Understanding the complex interplay between these activators and GDF-11 provides valuable insights into the regulatory network governing GDF-11 activity. This knowledge may contribute to the development of targeted interventions for modulating GDF-11 levels in various physiological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189, a selective BMP type I receptor inhibitor, indirectly activates GDF-11 by blocking the BMP signaling pathway. Inhibition of BMP signaling relieves the repression on GDF-11 expression, leading to increased GDF-11 levels. LDN-193189's role as an indirect activator highlights the interplay between BMP signaling and GDF-11 regulation, providing a potential avenue for modulating GDF-11 levels in various cellular contexts. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, an AMP-activated protein kinase (AMPK) inhibitor, indirectly activates GDF-11 by suppressing AMPK activity. Inhibition of AMPK releases the repression on GDF-11 expression, leading to elevated GDF-11 levels. Dorsomorphin's role as an indirect activator emphasizes the regulatory crosstalk between AMPK signaling and GDF-11 expression, suggesting a potential mechanism for modulating GDF-11 levels in different physiological contexts. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117, a selective ALK2 inhibitor, indirectly activates GDF-11 by inhibiting ALK2, a BMP type I receptor. Inhibition of ALK2 relieves the repression on GDF-11 expression, leading to elevated GDF-11 levels. LDN-214117's role as an indirect activator highlights the regulatory interplay between ALK2 signaling and GDF-11 expression, suggesting a potential avenue for modulating GDF-11 levels in different cellular and tissue contexts. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox, a selective inhibitor of the TGF-β type I receptor ALK5, indirectly activates GDF-11 by blocking TGF-β signaling. Inhibition of TGF-β signaling relieves the repression on GDF-11 expression, resulting in increased GDF-11 levels. RepSox's role as an indirect activator underscores the intricate balance between TGF-β signaling and GDF-11 regulation, offering insights into potential strategies for modulating GDF-11 levels in diverse cellular environments. | ||||||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
LDN-212854, a selective BMP receptor inhibitor, indirectly activates GDF-11 by blocking BMP signaling. Inhibition of BMP signaling by LDN-212854 releases the repression on GDF-11 expression, leading to elevated GDF-11 levels. LDN-212854's role as an indirect activator highlights the regulatory crosstalk between BMP signaling and GDF-11 regulation, suggesting a potential avenue for modulating GDF-11 levels in different cellular and tissue contexts. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1, a selective ALK2 inhibitor, indirectly activates GDF-11 by inhibiting ALK2, a BMP type I receptor. Inhibition of ALK2 relieves the repression on GDF-11 expression, leading to elevated GDF-11 levels. DMH1's role as an indirect activator emphasizes the regulatory interplay between ALK2 signaling and GDF-11 expression, suggesting a potential avenue for modulating GDF-11 levels in different cellular and tissue contexts. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, an HDAC inhibitor, indirectly activates GDF-11 by modulating histone acetylation. Inhibition of HDAC activity by Valproic Acid enhances the expression of GDF-11, leading to increased GDF-11 levels. Valproic Acid's role as an indirect activator suggests a potential epigenetic mechanism for modulating GDF-11 expression and function, providing insights into the regulatory pathways governing GDF-11 levels. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT, a γ-secretase inhibitor, indirectly activates GDF-11 by blocking Notch signaling. Inhibition of Notch signaling by DAPT relieves the repression on GDF-11 expression, resulting in increased GDF-11 levels. DAPT's role as an indirect activator underscores the regulatory crosstalk between Notch signaling and GDF-11 regulation, offering insights into potential strategies for modulating GDF-11 levels in diverse cellular environments. | ||||||